Fevers Since Age Six: Treating Before the Genotype Comes Back
His attack pattern points toward one periodic fever syndrome over another, but the confirmatory genetic panel is weeks away. The team has to decide how much diagnostic certainty a first anti-IL-1 dose actually requires.
Owen T., a 19-year-old college sophomore of Northern European descent, has missed two sets of final exams in the past three years to episodes he has learned to recognize before anyone else in his life can — puffy eyelids first, then a tender, migrating band of redness over one thigh or forearm that tracks with the underlying muscle rather than sitting still, followed within a day by fever that climbs to 39-40°C and abdominal pain severe enough that an emergency room once worked him up for appendicitis before the episode simply ended on its own. The pattern has repeated roughly monthly since he was six, each episode lasting five to nine days — longer than the three-to-five-day episodes more typical of the mevalonate-kinase-driven periodic fevers, and closer to the duration classically described in TNF receptor-associated periodic syndrome. His father has described “unexplained fever spells” of his own that were never formally worked up, a detail that, taken alone, does not distinguish an autosomal dominant pattern from a recessive one carried silently by both parents.
A genetic panel covering TNFRSF1A and MVK was sent three weeks ago; results are expected in another five to six. In the meantime, his CRP during a flare runs above 100 mg/L and normalizes between attacks — confirming the attacks are genuinely inflammatory rather than a functional or psychogenic pattern, but not distinguishing which specific periodic fever syndrome is driving them. He has never had the oral aphthous ulcers or diarrhea more typical of a mevalonate kinase phenotype, and his sustained periorbital edema is a finding described more often in TRAPS than in HIDS/MKD — real, phenotype-level evidence that argues for one diagnosis over the other well before either can be genetically confirmed.
Both candidate diagnoses share a treatment target the team already knows how to hit. The disagreement in front of them is not about the destination, but about whether a nineteen-year-old on the edge of losing another semester's worth of exams should wait for a result that will refine the plan, or start now on a drug reversible enough that starting early does not actually cost him the conversation waiting was meant to protect.
How much certainty does a first dose actually need
I don't think we should make him wait five more weeks. He has already lost two exam periods to this, his phenotype — the duration, the periorbital edema — points more toward TRAPS than HIDS, and critically, the CLUSTER trial — De Benedetti and colleagues, 2018 — ran three separate cohorts under one umbrella protocol, and TRAPS and HIDS/MKD were two of them. Only the FMF cohort was defined by colchicine resistance; the other two weren't, which is exactly why the trial covers both of his candidate diagnoses rather than just one. Canakinumab is labeled for both. Whichever this turns out to be, IL-1 blockade is very likely the right first move, and I'd start now.
I want to slow down on one specific point, not the treatment logic generally. TRAPS is autosomal dominant; HIDS/MKD is autosomal recessive. That distinction genuinely changes what we tell his younger sibling about her own risk, and what we eventually tell him about his own children's risk — and once he's started feeling better on a drug, that conversation tends to lose urgency for a family, even though the genetics haven't changed at all.
I'm not arguing his exam schedule doesn't matter. I'm arguing that starting treatment doesn't have to mean closing the door on getting that counseling conversation right, and I'd want us to be deliberate that it stays scheduled rather than assuming it will happen naturally once he's feeling better.
I think both of you are right about different things, and the drug choice is actually what reconciles them. Anakinra's half-life is measured in hours, not weeks — starting it now isn't a five-year commitment the way starting canakinumab or an older TRAPS-specific option like etanercept would be. Bulua and colleagues' open-label dose-escalation study of etanercept in genetically confirmed TRAPS found real but incomplete symptom control, which is part of why anti-IL-1 therapy has become the preferred first approach regardless of which specific periodic fever syndrome this turns out to be. I'll concede the asymmetry in my own position: canakinumab carries the label for both candidate diagnoses and anakinra carries neither, so I'm arguing for the off-label drug on reversibility, not on evidence.
Starting anakinra now treats his active disease without pre-empting anything the genetics conversation needs — if MVK comes back positive, there's even a modest, real trial (Simon et al.) suggesting simvastatin as a genotype-specific adjunct worth discussing then, not before.
Anakinra was started that week rather than held for the genetic panel, with the genetic-counseling appointment kept on the calendar independent of how he responds — the team's explicit way of honoring the Medical Geneticist's concern without asking him to spend a sixth week in the pattern he's already lived with for over a decade.
Not agreed: whether, once the genotype does return, a confirmed TRAPS diagnosis should prompt a trial off anakinra onto a longer-interval agent like canakinumab, or whether a drug already working is worth leaving alone. The Rheumatologist would revisit dosing interval once the picture is genetically clear; the Clinical Pharmacologist argued that switching a working, reversible regimen for convenience alone reintroduces exactly the kind of unforced commitment the anakinra choice was meant to avoid. Both agreed to make that call together once the result is actually in hand, not before.